http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
악성 흉막액에 대한 흉막강내 OK - 432 주입의 치료 효과
방영주(Yung Jue Bang),서철원(Chol Won Seo),이재훈(Jae Hoon Lee),신동복(Dong Bok Shin),강윤구(Yoon Koo Kang),박근칠(Keun Chil Park),김노경(Noe Kyeong Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.4
N/A OK-432 has been shown to have antitumor activity in cancer patients, and intrapleural injection of OK-432 had also been shown to cause reduction or disappearance of pleural effusions and/or tumor cells in pleural effusions of cancer patients. Forty patients with malignant pleural effusions were treated with intrapleural administration of OK-432. Their age ranged from 20 to 80 years with a median of 56 years, and the male to female ratio was 24:16. Primary tumor sites were lung in 30 patients, stomach in 3, colon in 1, ovary in 1, and 5 patients had adenocarcinoma of unknown primary site. Cytologic examinations of pleural fluid were positive in 30 patients, and 10 patients without cytologic proof had exudative effusions with elevated levels of carcinoembryonic antigen. Their performance status was ECOG grade 1 in 9, 2 in 18, and 3 in 13 patients. One to three courses of intrapleural injection of OK-432 were tried weekly (mean 1.3 courses) without any concomitant anticancer treatment. The responses were categorized as objective response or failure. Seven patients were not evaluable for response because of early death without pleural effusion in two, protocol violation in one, and lost to follow-up in four. Twenty-four patients (72.7%) achieved objective responses among 33 evaluable patients. Response duration ranged from 4+ to 59 weeks with a median of 52 weeks. Common toxicities included fever and chill (38/52 courses), and pleuritic chest pain (24/52), but those symptoms were tolerable. These results show that intrapleural administration of OK-432 appears to be effective in the control of malignant pleural effusions with acceptable toxicity.